Edward Ryan

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Transformation of the developing world: socioeconomic matrix
    Dennis Carroll
    US Agency for International Development, Wsahington, DC, USA
    Emerg Infect Dis 10:2049. 2004
  2. pmc Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide
    Mohammad Murshid Alam
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America International Centre for Diarrheal Disease Research, Bangladesh ICDDR, B, Dhaka, Bangladesh
    PLoS Negl Trop Dis 8:e2683. 2014
  3. pmc High depth, whole-genome sequencing of cholera isolates from Haiti and the Dominican Republic
    Rachel Sealfon
    Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
    BMC Genomics 13:468. 2012
  4. pmc Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice
    A A Tarique
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Vaccine Immunol 19:594-602. 2012
  5. ncbi request reprint Illness after international travel
    Edward T Ryan
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 347:505-16. 2002
  6. pmc Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice
    Chandrabali Ghose
    Division of Infectious Diseases, Massachusetts General Hospital, Jackson 504, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 75:2826-32. 2007
  7. ncbi request reprint Live attenuated oral cholera vaccines
    Edward T Ryan
    Massachusetts General Hospital Tropical and Geographic Medicine Center, Division of Infectious Diseases, Jackson 504 55 Fruit Street, Boston, MA 02114, USA
    Expert Rev Vaccines 5:483-94. 2006
  8. ncbi request reprint Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera
    E T Ryan
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 184:643-7. 2001
  9. ncbi request reprint Cholera vaccines
    E T Ryan
    Tropical and Geographic Medicine Center, Travelers Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 31:561-5. 2000
  10. pmc Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice
    Julianne E Rollenhagen
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    Vaccine 27:4917-22. 2009

Collaborators

Detail Information

Publications49

  1. pmc Transformation of the developing world: socioeconomic matrix
    Dennis Carroll
    US Agency for International Development, Wsahington, DC, USA
    Emerg Infect Dis 10:2049. 2004
  2. pmc Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide
    Mohammad Murshid Alam
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America International Centre for Diarrheal Disease Research, Bangladesh ICDDR, B, Dhaka, Bangladesh
    PLoS Negl Trop Dis 8:e2683. 2014
    ..Serogroup specificity in Vibrio cholerae is determined by the O-specific polysaccharide (OSP) of lipopolysaccharide (LPS). Generally, polysaccharides are poorly immunogenic, especially in young children...
  3. pmc High depth, whole-genome sequencing of cholera isolates from Haiti and the Dominican Republic
    Rachel Sealfon
    Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
    BMC Genomics 13:468. 2012
    ..cholerae isolates to a high depth of coverage (>2000x); four of the seven isolates were previously sequenced...
  4. pmc Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice
    A A Tarique
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Vaccine Immunol 19:594-602. 2012
    ..Our results suggest that transcutaneous and subcutaneous boosting with a neoglycoconjugate following oral cholera vaccination may be an effective strategy to prolong protective immune responses against V. cholerae...
  5. ncbi request reprint Illness after international travel
    Edward T Ryan
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 347:505-16. 2002
  6. pmc Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice
    Chandrabali Ghose
    Division of Infectious Diseases, Massachusetts General Hospital, Jackson 504, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 75:2826-32. 2007
    ..Our results suggest that transcutaneous immunization with CDA toxoid may be a feasible immunization strategy against C. difficile, an important cause of morbidity and mortality against which current preventative strategies are failing...
  7. ncbi request reprint Live attenuated oral cholera vaccines
    Edward T Ryan
    Massachusetts General Hospital Tropical and Geographic Medicine Center, Division of Infectious Diseases, Jackson 504 55 Fruit Street, Boston, MA 02114, USA
    Expert Rev Vaccines 5:483-94. 2006
    ..cholerae O139, including CVD 112 and Bengal-15. Live, orally administered, attenuated cholera vaccines are in various stages of development and evaluation...
  8. ncbi request reprint Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera
    E T Ryan
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 184:643-7. 2001
    ..The ability to generate specific mucosal immune responses in reproductive tract tissues after intestinal presentation of antigen could facilitate development of vaccines effective against reproductive tract pathogens...
  9. ncbi request reprint Cholera vaccines
    E T Ryan
    Tropical and Geographic Medicine Center, Travelers Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 31:561-5. 2000
    ..cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed...
  10. pmc Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice
    Julianne E Rollenhagen
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    Vaccine 27:4917-22. 2009
    ..Our results suggest that transcutaneously applied synthetic V. cholerae neoglycoconjugate is safe and immunogenic, but predominantly induces systemic LPS responses of the IgG isotype...
  11. pmc Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice
    Julianne E Rollenhagen
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Infect Immun 74:5834-9. 2006
    ..001). Our results suggest that transcutaneous immunization with TcpA and an immunoadjuvant induces protective anti-TcpA immune responses. Anti-TcpA responses may contribute to an optimal cholera vaccine...
  12. ncbi request reprint Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies
    Manohar John
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Jackson 504, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Vaccine 20:2720-6. 2002
    ..Our results suggest that combination oral and transcutaneous immunization strategies may most prominently induce both mucosal and systemic humoral responses...
  13. pmc Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae
    Long Hang
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 100:8508-13. 2003
    ..cholerae O1. In vivo-induced antigen technology provides a simple method for identifying microbial proteins expressed during human infection, but not during in vitro growth...
  14. pmc Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea
    Eric J Nelson
    Howard Hughes Medical Institute and Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Proc Natl Acad Sci U S A 104:19091-6. 2007
    ..cholerae. If lytic phage are present, viable counts of V. cholerae drop, stools become DF(-), other microorganisms bloom, and cholera transmission is reduced...
  15. pmc Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh
    Jason B Harris
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS Negl Trop Dis 3:e403. 2009
    ..However, the immunomodulatory effects of concomitant intestinal parasitic infection in cholera patients have not been systematically evaluated...
  16. pmc Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis
    Sean M Rollins
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 3:e1824. 2008
    ..anthracis infection. Identification of L-alanine amidases with B. anthracis specificity may suggest new potential therapeutic targets...
  17. pmc Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh
    Jason B Harris
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS Negl Trop Dis 2:e221. 2008
    ..Despite recent progress in understanding the molecular basis of Vibrio cholerae pathogenesis, there is relatively little knowledge of the factors that determine the variability in human susceptibility to V. cholerae infection...
  18. pmc Proteomic analysis of Vibrio cholerae in human stool
    Regina C LaRocque
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Infect Immun 76:4145-51. 2008
    ..We identified a number of these in vivo expressed proteins as immunogenic during human infection. To our knowledge, this is the first characterization of the proteome of a pathogenic bacteria recovered from a natural host...
  19. doi request reprint Pre-travel health advice-seeking behavior among US international travelers departing from Boston Logan International Airport
    Regina C LaRocque
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    J Travel Med 17:387-91. 2010
    ..Despite this, data about sources of health information used by international travelers are limited...
  20. pmc Comparative proteomic analysis of the PhoP regulon in Salmonella enterica serovar Typhi versus Typhimurium
    Richelle C Charles
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 4:e6994. 2009
    ..The PhoP regulon is a well studied two component (PhoP/Q) coordinately regulated network of genes whose expression is required for intracellular survival of S. enterica...
  21. pmc Clinical outcomes in household contacts of patients with cholera in Bangladesh
    Ana A Weil
    International Centre for Diarrhoeal Disease Research Dhaka, Bangladesh
    Clin Infect Dis 49:1473-9. 2009
    ..cholerae infection and associated clinical symptoms in household contacts of patients with cholera and to identify risk factors for development of severe dehydration in this cohort...
  22. pmc Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technology
    Richelle C Charles
    Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Clin Vaccine Immunol 17:1188-95. 2010
    ..Typhi-infected patients and detected anti-HlyE responses at the time of clinical presentation in patients but not in controls. These findings could assist in the development of improved diagnostic assays...
  23. pmc Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity
    Jason B Harris
    Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 73:7422-7. 2005
    ..Based on this epidemiologic evidence, we propose a hypothesis for understanding the association between blood group O and the risk of infection with V. cholerae O1 and O139 as well as the risk of developing severe symptoms once infected...
  24. pmc Transcriptional profiling of Vibrio cholerae recovered directly from patient specimens during early and late stages of human infection
    Regina C LaRocque
    Division of Infectious Diseases, Gray Jackson 504, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 73:4488-93. 2005
    ..These findings provide a more detailed assessment of the transcriptome of V. cholerae in the human host than previous studies of organisms in stool alone and have implications for cholera control and the design of improved vaccines...
  25. ncbi request reprint Prevention of infection in adult travelers after solid organ transplantation
    Camille Nelson Kotton
    Transplant Infectious Disease and Compromised Host Program, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
    Am J Transplant 5:8-14. 2005
    ..This review considers risks of international travel to adult solid organ transplant recipients and the use of vaccines and prophylactic agents in this population...
  26. ncbi request reprint Postgenomic approaches to cholera vaccine development
    Regina C LaRocque
    Division of Infectious Diseases, Massachusetts General Hospital, GRJ 504, 55 Fruit Street, Boston, MA 02114, USA
    Expert Rev Vaccines 5:337-46. 2006
    ..This work holds promise for the identification of bacterial targets of protective human immune responses and may contribute to the development of a new generation of cholera vaccines...
  27. pmc Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi
    Jason B Harris
    Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Infect Immun 74:5161-8. 2006
    ..Serovar Typhi antigens identified by IVIAT warrant further evaluation for their contributions to pathogenesis, and they may have diagnostic, therapeutic, or preventive uses...
  28. ncbi request reprint Medical problems in the returning expatriate
    Natasha Hochberg
    Department of Internal Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Occup Environ Med 4:205-19. 2004
    ..Many infections associated with long-term overseas deployment may include dermatologic manifestations, including filariasis and leishmaniasis...
  29. ncbi request reprint Vaccination strategies
    Louise C Ivers
    Tropical and Geographic Medicine Center, Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Jackson 504, Boston, MA 02114, USA
    Clin Occup Environ Med 4:27-43. 2004
    ..When considering work-force productivity, work-force infectivity, and the common good, careful consideration should be given to establishing at least a basic immunization program for in-country nationals and their dependents...
  30. pmc Diarrheal epidemics in Dhaka, Bangladesh, during three consecutive floods: 1988, 1998, and 2004
    Brian S Schwartz
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA
    Am J Trop Med Hyg 74:1067-73. 2006
    ..Our findings suggest that cholera is the predominant cause of flood-associated diarrheal epidemics in Dhaka, but that other organisms spread by the fecal-oral route also contribute...
  31. ncbi request reprint Yersinia pestis and the plague
    Sarah E Rollins
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Am J Clin Pathol 119:S78-85. 2003
    ..Advances also have been made in rapid diagnosis, the understanding of immune responses during plague, and vaccine development...
  32. ncbi request reprint Case records of the Massachusetts General Hospital. Case 39-2005. A 63-year-old woman with a positive serologic test for syphilis and persistent eosinophilia
    Edward T Ryan
    Tropical and Geographic Medicine Center, Massachusetts General Hospital, USA
    N Engl J Med 353:2697-705. 2005
  33. ncbi request reprint Infectious diseases of severe weather-related and flood-related natural disasters
    Louise C Ivers
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Curr Opin Infect Dis 19:408-14. 2006
    ..The present review will focus on some of the possible infectious disease consequences of disastrous natural phenomena and severe weather, with a particular emphasis on infections associated with floods and the destruction of infrastructure...
  34. pmc Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Mohakhali, Dhaka 1212, Bangladesh
    Infect Immun 71:4808-14. 2003
    ....
  35. ncbi request reprint Cryptosporidiosis among Bangladeshi children with diarrhea: a prospective, matched, case-control study of clinical features, epidemiology and systemic antibody responses
    Wasif A Khan
    Clinical Sciences Division, Centre for Health and Population Research, International Center for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh, GPO Box 128, Dhaka 1000, Bangladesh
    Am J Trop Med Hyg 71:412-9. 2004
    ..However, there was a significant difference between children with acute and persistent diarrhea in changes in both IgA and IgM levels, with persistent diarrhea being associated with a decrease in levels of both antibodies...
  36. ncbi request reprint Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh
    Debasish Saha
    International Centre for Diarrheal Disease Research, Bangladesh
    J Infect Dis 189:2318-22. 2004
    ..No association between baseline vibriocidal titer and protection from V. cholerae O139 infection was found. Our findings suggest that the vibriocidal antibody is an incomplete predictor of protection from V. cholerae infection...
  37. pmc The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139
    Muhammad Asaduzzaman
    International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh
    Infect Immun 72:4448-54. 2004
    ..These results demonstrate that TcpA is immunogenic following natural V. cholerae infection and suggest that immune responses to this antigen should be evaluated for potential protection against subsequent life-threatening illness...
  38. pmc Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka
    Infect Immun 73:6577-83. 2005
    ..cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines...
  39. pmc Hyperinfectivity of human-passaged Vibrio cholerae can be modeled by growth in the infant mouse
    Ashfaqul Alam
    International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
    Infect Immun 73:6674-9. 2005
    ..cholerae as well as the contribution of three type IV pili to the phenotype...
  40. pmc Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1
    Channa R Jayasekera
    International Centre for Diarrhoeal Disease Research, Bangladesh
    J Infect Dis 198:1055-61. 2008
    ..The presence of antigen-specific memory B cells may therefore be a more direct measure of protection than serum antibody responses...
  41. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa
    Anne C Moore
    N Engl J Med 346:2069-76. 2002
  42. doi request reprint Management of travellers' diarrhoea
    David R Hill
    National Travel Health Network and Centre, and London School of Hygiene and Tropical Medicine, Hospital for Tropical Diseases, London WC1E 6JB
    BMJ 337:a1746. 2008
  43. ncbi request reprint Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh
    Michael L Bennish
    Africa Centre for Health and Population Studies, Mtubatuba, South Africa
    Clin Infect Dis 42:356-62. 2006
    ..Shigella dysenteriae type 1 also expresses Stx. However, the effect of antimicrobial therapy on Stx release and the risk of HUS in humans is unknown...
  44. ncbi request reprint Bacteremia, fever, and splenomegaly caused by a newly recognized bartonella species
    Marina E Eremeeva
    Centers for Disease Control and Prevention, Atlanta, USA
    N Engl J Med 356:2381-7. 2007
    ..We characterized this isolate, including its ability to cause fever and sustained bacteremia in a rhesus macaque. The route of infection and burden of human disease associated with this newly described pathogen are currently unknown...
  45. ncbi request reprint The practice of travel medicine: guidelines by the Infectious Diseases Society of America
    David R Hill
    National Travel Health Network and Centre, London School of Hygiene and Tropical Medicine, London, WC1E 6AU, England
    Clin Infect Dis 43:1499-539. 2006

Research Grants13

  1. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2002
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  2. Global TravEpiNet: Global Travelers' Health National Research Center Consortium
    Edward Ryan; Fiscal Year: 2007
    ..We would use data generated through this network in an attempt to estimate national vaccine coverage rates (and other preventative strategies) among international travelers. ..
  3. Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15
    Edward Ryan; Fiscal Year: 2007
    ....
  4. High throughput proteomic analysis of Salmonella enterica
    Edward Ryan; Fiscal Year: 2007
    ....
  5. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2006
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  6. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2005
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  7. Application of IVIAT to Bacillus anthracis
    Edward Ryan; Fiscal Year: 2004
    ..IVIAT is an established protocol in our laboratory, and this preliminary collaborative study should lay a foundation for subsequent analysis of identified B. anthracis genes and their products. ..
  8. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2004
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  9. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2003
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..